BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 16125822)

  • 1. Non-CpG cytosine methylation of p53 exon 5 in non-small cell lung carcinoma.
    Kouidou S; Agidou T; Kyrkou A; Andreou A; Katopodi T; Georgiou E; Krikelis D; Dimitriadou A; Spanos P; Tsilikas C; Destouni H; Tzimagiorgis G
    Lung Cancer; 2005 Dec; 50(3):299-307. PubMed ID: 16125822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation and repeats in silent and nonsense mutations of p53.
    Kouidou S; Malousi A; Maglaveras N
    Mutat Res; 2006 Jul; 599(1-2):167-77. PubMed ID: 16620878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General implications for CpG hot spot mutations: methylation patterns of the human iduronate-2-sulfatase gene locus.
    Tomatsu S; Orii KO; Bi Y; Gutierrez MA; Nishioka T; Yamaguchi S; Kondo N; Orii T; Noguchi A; Sly WS
    Hum Mutat; 2004 Jun; 23(6):590-8. PubMed ID: 15146464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
    Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
    Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers.
    Tornaletti S; Pfeifer GP
    Oncogene; 1995 Apr; 10(8):1493-9. PubMed ID: 7731703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
    Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
    Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation markers of surfactant proteins in lung cancer.
    Lin Z; Thomas NJ; Bibikova M; Seifart C; Wang Y; Guo X; Wang G; Vollmer E; Goldmann T; Garcia EW; Zhou L; Fan JB; Floros J
    Int J Oncol; 2007 Jul; 31(1):181-91. PubMed ID: 17549420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hierarchical clustering of lung cancer cell lines using DNA methylation markers.
    Virmani AK; Tsou JA; Siegmund KD; Shen LY; Long TI; Laird PW; Gazdar AF; Laird-Offringa IA
    Cancer Epidemiol Biomarkers Prev; 2002 Mar; 11(3):291-7. PubMed ID: 11895880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.
    Hsu HS; Wang YC; Tseng RC; Chang JW; Chen JT; Shih CM; Chen CY; Wang YC
    Clin Cancer Res; 2004 Jul; 10(14):4734-41. PubMed ID: 15269146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferential carcinogen-DNA adduct formation at codons 12 and 14 in the human K-ras gene and their possible mechanisms.
    Hu W; Feng Z; Tang MS
    Biochemistry; 2003 Aug; 42(33):10012-23. PubMed ID: 12924950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational, epigenetic and expressional analyses of caveolin-1 gene in breast cancers.
    Chen ST; Lin SY; Yeh KT; Kuo SJ; Chan WL; Chu YP; Chang JG
    Int J Mol Med; 2004 Oct; 14(4):577-82. PubMed ID: 15375584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
    Kouidou S; Malousi A; Kyventidis A; Fragou A; Maglaveras N
    Breast Cancer Res Treat; 2007 Dec; 106(3):351-60. PubMed ID: 17505880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer.
    Ehrich M; Field JK; Liloglou T; Xinarianos G; Oeth P; Nelson MR; Cantor CR; van den Boom D
    Cancer Res; 2006 Nov; 66(22):10911-8. PubMed ID: 17108128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in methylation patterns in the methylation boundary region of IDS gene in Hunter syndrome patients: implications for CpG hot spot mutations.
    Tomatsu S; Sukegawa K; Trandafirescu GG; Gutierrez MA; Nishioka T; Yamaguchi S; Orii T; Froissart R; Maire I; Chabas A; Cooper A; Di Natale P; Gal A; Noguchi A; Sly WS
    Eur J Hum Genet; 2006 Jul; 14(7):838-45. PubMed ID: 16617305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation patterns of the human beta-glucuronidase gene locus: boundaries of methylation and general implications for frequent point mutations at CpG dinucleotides.
    Tomatsu S; Orii KO; Islam MR; Shah GN; Grubb JH; Sukegawa K; Suzuki Y; Orii T; Kondo N; Sly WS
    Genomics; 2002 Mar; 79(3):363-75. PubMed ID: 11863366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
    Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
    Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
    Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.
    Skaug V; Ryberg D; Kure EH; Arab MO; Stangeland L; Myking AO; Haugen A
    Clin Cancer Res; 2000 Mar; 6(3):1031-7. PubMed ID: 10741731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.